Anifrolumab

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

The Anifrolumab PRIM Program

Anifrolumab Malignancy and Serious Infections Study

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Saphnelo Use in Females of Child-bearing Potential

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

Anifrolumab for Hidradenitis Suppurativa

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)

Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult Participants

Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue

Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus